pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
Daiichi Sankyo US projects
19 ClinicalTrials.gov programs sponsored by Daiichi Sankyo US.
Daiichi Sankyo US has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
10mg DS-8500a tablet
Daiichi Sankyo
Type 2 Diabetes Mellitus
1 trial -
CS-3150
Daiichi Sankyo
Diabetic Nephropathy
1 trial -
DS-1062a
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
DS-3939a
Daiichi Sankyo
Metastatic Solid Tumor, Advanced Solid Tumor
1 trial -
DS-5141b
Daiichi Sankyo
Duchenne Muscular Dystrophy
1 trial -
DS-8201a
Daiichi Sankyo
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer
1 trial -
DS3201-330
Daiichi Sankyo
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
DS7300-189
Daiichi Sankyo
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Datopotamab deruxtecan
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
EPCORITAMAB, RITUXIMAB
Daiichi Sankyo
Hematological Malignancies
1 trial -
HER3-DXd
Daiichi Sankyo
Advanced Solid Tumor
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Patritumab deruxtecan
Daiichi Sankyo
Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Patritumab deruxtecan
Daiichi Sankyo
Locally Advanced or Metastatic Solid Tumors
1 trial -
Quizartinib
Daiichi Sankyo
Acute Myeloid Leukemia
1 trial -
Raludotatug Deruxtecan
Daiichi Sankyo
Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)
1 trial -
Valemetostat Tosylate, Valemetostat Tosylate
Daiichi Sankyo
Relapsed/Refractory Peripheral T-Cell Lymphoma
1 trial -
olmesartan medoxomil
Daiichi Sankyo
Chronic Glomerulonephritis
1 trial
Frequently asked questions
How many clinical projects does Daiichi Sankyo US have?
19 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.